At the somatic level, inactivation of CDKN2A and CDKN2B has been identified as an important feature in a number of tumors, most notably melanomas and tumors in the CNS (Boström et al., 2001; Casula et al., 2019; Ghasimi et al., 2016; Gonzalez‐Zulueta et al., 1995; McNeal et al., 2015; Rousseau et al., 2003). The gene discussed is CDKN2B; the disease is melanoma.